![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
Novo Nordisk | driving change to defeat serious chronic diseases
Jan 31, 2025 · Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.
Who we are - Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in discovering and developing treatment for serious chronic disease, like diabetes and obesity.
Our heritage | Novo Nordisk | Driving change
Our history spans a century and it all began with two small Danish companies, Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium. After hearing of the discovery of insulin in 1921, Danish Nobel laureate August Krogh and …
What we do - Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in serious chronic disease treatment.
Our products - Novo Nordisk
Overview of Novo Nordisk pharmaceutical products within diabetes, obesity, haemophilia, human growth hormone and hormone replacement therapy.
Careers - Novo Nordisk
At Novo Nordisk, you will have the opportunity to build a life-changing career in a global business environment. Join us and make a difference.
Latest news - Novo Nordisk
Jan 8, 2025 · Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Financial results and events overview - Novo Nordisk
4 days ago · Novo Nordisk Executive Management and other members of senior management provided a full review of our strategy, operations and financial targets. Download the presentations and watch the webcast Annual General Meeting. 21 March 2024. We held our Annual General Meeting on 21 March 2024 at 14:00 CET.
News Details - novonordisk.com
Jan 17, 2025 · Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence. Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial ...
Our medicines | Diabetes medications | Obesity medication - Novo …
In some cases, healthcare professionals and patients can visit local Novo Nordisk websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources.